Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing
Open Access
- 18 March 2020
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy Nucleic Acids
- Vol. 20, 480-490
- https://doi.org/10.1016/j.omtn.2020.03.005
Abstract
No abstract availableFunding Information
- National Taiwan University Hospital (108-s4135)
- MOST (104-2314-B-002-041-MY3)
- Cardinal Tien Junior College of Healthcare and Management (CTCN-107-04)
This publication has 47 references indexed in Scilit:
- Molecular biology of hepatitis B virus infectionVirology, 2015
- A split-Cas9 architecture for inducible genome editing and transcription modulationNature Biotechnology, 2015
- Non-viral vectors for gene-based therapyNature Reviews Genetics, 2014
- Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNAScience, 2014
- An Efficient Antiviral Strategy for Targeting Hepatitis B Virus Genome Using Transcription Activator-Like Effector NucleasesMolecular Therapy, 2014
- Targeting Hepatitis B Virus With CRISPR/Cas9Molecular Therapy Nucleic Acids, 2014
- Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCPBiochemical and Biophysical Research Communications, 2014
- Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector NucleasesMolecular Therapy, 2013
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA.Proceedings of the National Academy of Sciences of the United States of America, 1987